Skip to main content
. 2021 Dec 29;14(1):49. doi: 10.3390/v14010049

Figure 5.

Figure 5

The IFN inhibitor or MRC-5IFNAR1− cell lines enhanced rabies virus (RABV) production in pilot-scale experiments. (A) The pilot production platform consists of 30 spinner flasks with a surface area of 1500 cm2 and a constant temperature flask-rotating machine. The MRC-5IFNAR1− cells and MRC-5 cells treated with both 2 μM TPCA-1 and Ruxolitinib 2 h before RABV infection were infected with the PM RABV strains at an MOI of 0.05 in 1500 square centimeter spinner flasks, respectively. Vero cells were infected with the aG RABV strains at a MOI of 0.001. (B) Representative cell status was recorded at 168 hpi. (C) The MRC-5 cells were treated with 4 μM TPCA-1, 4 μM Ruxolitinib, or both 2 μM TPCA-1 and Ruxolitinib 2 h before RABV infection. Viral titers in the culture supernatant were detected by focus-forming unit (FFU) assays at 96, 168, and 240 hpi. (D) The MRC-5 or MRC-5IFNAR1− cells were infected with RABV. Viral titers in the culture supernatant were detected by FFU assays at 96, 168, and 240 hpi. +: RABV infection; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns p ≥ 0.05.